The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2025 | Looking forward to the upcoming MYELOMAS meeting in Rome, Italy
Claudio Cerchione, MD, PhD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, shares his excitement for the upcoming MYELOMAS meeting in Rome, Italy, from October 10-11, 2025. Dr Cerchione discusses the meeting’s focus, including the latest advances in quadruplets, CAR-T versus bispecifics, and more. This interview took place at the 22nd International Myeloma Society (IMS) Annual Meeting in Toronto, Canada.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
The therapeutic and diagnostic revolution in multiple myeloma is going to continue and we are always facing a heterogeneous disease. That’s why MYELOMAS is the name of the meeting that we are going to realize on the 10th and 11th of October in Rome, the Hive Hotel, where we will in some way present the heterogeneity of the disease, starting from the biology tools, starting from the new aspects of the introduction of quadruplets in daily practice, the debate about which is better to anticipate CAR-T versus bispecific antibodies, and many other debates with really high-level international speakers integrating with Italian key opinion leaders, we wait for a lot of colleagues that will come with us...
The therapeutic and diagnostic revolution in multiple myeloma is going to continue and we are always facing a heterogeneous disease. That’s why MYELOMAS is the name of the meeting that we are going to realize on the 10th and 11th of October in Rome, the Hive Hotel, where we will in some way present the heterogeneity of the disease, starting from the biology tools, starting from the new aspects of the introduction of quadruplets in daily practice, the debate about which is better to anticipate CAR-T versus bispecific antibodies, and many other debates with really high-level international speakers integrating with Italian key opinion leaders, we wait for a lot of colleagues that will come with us. We have some travel grants for young under 40 investigators and I’m sure that this will be a brilliant event, realized by me and my colleagues of IRST, our institution located in Meldola, scientific responsibility on me and Gerardo Musuraca, honorary presidents of our scientific director Nicola Normanno and realized by our myeloma team we wait strongly for all of you in Rome on 10 and 11 October and if you have any curiosity contact us also about subscription we wait for you there
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Advisory board and/or Consultant and/or speaker for Abbvie, AMGEN, Astellas, Beigene, BMS, Curis, Glycomimetics, GSK, Immunogen, Janssen, Jazz, Karyopharm, Menarini – Stemline, Oncopeptides, Pfizer, Sanofi, Servier, Skyline DX, Stemline, Takeda.
